Navigation Links
Masimo Corporation Adopts Stockholder Rights Plan
Date:11/9/2007

IRVINE, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI) the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, announced today that the Pricing Committee of its Board of Directors has formally adopted a stockholder rights plan.

"This plan is designed to enhance the Board's ability to protect stockholders against unsolicited attempts to acquire control of the company that do not offer an adequate price to all stockholders or are otherwise not in the best interests of the company and its stockholders and customers," said Joe E. Kiani, Chairman and CEO of Masimo. "The plan is intended to provide the Board with sufficient time to consider any and all alternatives to such an action."

As disclosed in the Company's previous filings with the Securities and Exchange Commission in connection with its initial public offering, the Company anticipated adopting a stockholder rights plan following the completion of its IPO, which occurred on August 13, 2007. The Plan was not adopted in response to any attempt to acquire the Company. Under the Plan, each common stockholder of the Company at the close of business on November 26, 2007 will receive a dividend of one right for each share of the Company's common stock held of record on that date. Each right will entitle the holder to purchase from the Company, in certain circumstances described below, one one-thousandth of a share of newly-created Series A junior participating preferred stock of the Company for an initial purchase price of $136 per share. The rights distribution will not be taxable to stockholders and the distribution of rights under the Plan will not interfere with the Company's business plans or be dilutive to or affect the Company's reported per share results.

Initially the rights will be represented by the Company's common stock certificates and will not be exercisable. The rights will generally become exercisable ten business days after any person has become the beneficial owner of 15% or more of the Company's common stock or has commenced a tender or exchange offer which, if consummated, would result in any person becoming the beneficial owner of 15% or more of the common stock of the Company.

If any person becomes the beneficial owner of 15% or more of the Company's common stock, each right will entitle the holder, other than the acquiring person, to purchase Company common stock or common stock of the acquiring person having a value of twice the exercise price. In addition, if there is a business combination between the Company and the acquiring person, or in certain other circumstances, each right that is not previously exercised will entitle the holder (other than the acquiring person) to purchase shares of common stock of the acquiring person at one-half of the market price of those shares.

The Company may redeem the rights at a price of $0.001 per right at any time prior to the date on which any person has become the beneficial owner of 15% or more of the common stock of the Company. The rights will expire on November 8, 2017, unless earlier exchanged or redeemed.

The Company will file with the Securities and Exchange Commission a Current Report on Form 8-K describing the stockholder rights plan. The Form 8-

K will include a copy of the Rights Agreement governing the Plan as an exhibit.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Masimo Corporation

Investors:

Mark P. de Raad

Executive Vice President and

Chief Financial Officer

(949) 297-7080

mderaad@masimo.com

Media:

Tom McCall

Vice President, Corporate Communications

(949) 297-7075

tmccall@masimo.com

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad-57, APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet and Pulse CO-Oximeter are trademarks of Masimo Corp.


'/>"/>
SOURCE Masimo
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
2. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
3. Breaking Studies - Masimos Technologies the Focus of Multiple Clinical Studies at Last Weeks American Society of Anesthesiologists Annual Meeting
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
11. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica ... Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home 2017,” ... community. “Coming Home 2017” will be held on Friday January 27 through ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million women ... of recovery, they often feel shame for having struggled with an eating disorder as ... the workshop, “Rising Strong in Life After an Eating Disorder” -- to be featured ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... A new ... donate items they no longer use or need, from clothes to couches to dressers ... unwanted items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... ... ... Doctor C LLC, a company based out of Arizona that focuses on ... marketing and distribution of its product, The Right C. , The Right C is ... traditional vitamin C supplements. At the trade show, Doctor C had the opportunity to ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an ... lives, recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting ... its large range of supplements that keep the body functioning at its peak ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
(Date:1/20/2017)... Fla. , Jan. 20, 2017 Wells Specialty ... at 3796 Howell Branch Rd in Winter Park, ... Winter Park . Operations have been consolidated into ... Pharmacy is also pleased to announce that Chad Tomlinson ... President of the Company effective immediately. Mr. Tomlinson is a ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
Breaking Medicine Technology: